Mk 677 vs Hgh
Which Is Right for You? Complete Comparison (2026)
Detailed MK-677 (ibutamoren) vs HGH (somatropin) comparison. Oral pill vs daily injection, $50–150/month vs $800–2,000+, IGF-1 response, legal status.
Mk 677 vs Hgh: At a Glance
- ✓Non-peptide oral ghrelin mimetic — no injection required
- ✓Sustained GH and IGF-1 elevation for 24 hours per dose
- ✓Increases appetite significantly (ghrelin pathway activation)
- ✓Does not suppress natural GH pulsatility
- ✓Not a SARM despite common misclassification
- ✓Direct exogenous GH — bypasses pituitary signaling entirely
- ✓Provides predictable, dose-dependent GH and IGF-1 levels
- ✓FDA-approved for GH deficiency, Turner syndrome, and other conditions
- ✓Suppresses endogenous GH production during use
- ✓Half-life approximately 3-4 hours (daily injection)
Detailed Comparison
| Feature | Mk 677 | Hgh |
|---|---|---|
| Mechanism | Oral growth hormone secretagogue | Recombinant human growth hormoneBest |
| Dosing | 10-25 mg orally once daily | 1-4 IU daily SC (anti-aging); higher for clinical GH deficiency |
| Administration | Oral | Subcutaneous injection daily |
| Half-life | ~4-6 hours (but GH elevation lasts ~24 hours) | ~3-4 hours |
| FDA Status | Not FDA-approved — investigational drug | FDA-approved (multiple brands: Genotropin, Humatrope, Norditropin) |
| Key Trial | Nass R et al. Ann Intern Med 2008 — GH secretion in elderly | Rudman D et al. NEJM 1990 — landmark GH in aging study |
| Side Effects | Increased appetite, water retention, insulin resistance, lethargy | Water retention, joint pain, carpal tunnel, insulin resistance, potential tumor growth risk |
Which Should You Choose?
MK-677 (Ibutamoren) (oral growth hormone secretagogue) and Human Growth Hormone (Somatropin) (recombinant human growth hormone) serve different clinical roles despite both being in the GH secretagogue (oral) space. MK-677 (Ibutamoren) non-peptide oral ghrelin receptor agonist that stimulates sustained gh and igf-1 elevation for 24 hours from a single oral dose. Human Growth Hormone (Somatropin) direct exogenous gh replacement that bypasses the pituitary.
Whichever you choose, track your protocol in Shotlee to build clean data for dose optimization and outcomes comparison.
Making an Informed Choice Between Mk 677 and Hgh
Choosing between Mk 677 and Hgh depends on multiple individual factors including your specific health goals, tolerance profile, insurance coverage, and prescriber recommendation. While clinical trial data provides population-level efficacy and safety comparisons, your personal response may differ based on genetics, baseline health, concurrent conditions, and lifestyle factors. Use this comparison as a starting framework and discuss the specifics with your healthcare provider.
Head-to-head clinical trial data between Mk 677 and Hgh is the gold standard for comparison, but such direct comparisons are not always available for every pair of compounds. Where head-to-head data is lacking, cross-trial comparisons provide useful but imperfect approximations — differences in patient populations, trial design, and endpoint definitions mean that numbers from separate trials are not directly interchangeable. Keep this context in mind when evaluating the comparison data presented here.
Tracking your personal response data in Shotlee is particularly valuable when switching between medications or considering a change. By documenting your outcomes on your current protocol — including efficacy metrics, side effect profile, adherence rate, and quality of life measures — you create an objective baseline for comparison if you transition to the alternative compound. This data transforms a subjective switching decision into an evidence-based protocol optimization.
Mk 677 vs Hgh: Frequently Asked Questions
MK-677 raises IGF-1 by 30–60% depending on dose. HGH can produce a larger, more controllable rise — particularly at 2–4 IU/day. For borderline-low IGF-1 or longevity goals, MK-677 is often sufficient. For diagnosed GH deficiency, HGH is more potent and appropriate.
No. MK-677 stimulates the pituitary to release its own GH — the natural feedback loop remains intact. Exogenous HGH, by contrast, progressively suppresses pituitary GH output through negative feedback. No PCT is needed for MK-677.
MK-677 as a research compound costs approximately $50–150/month. Pharmaceutical HGH (Norditropin, Humatrope, etc.) costs $800–$2,000+ per month in the US without insurance. Compounded or overseas HGH is cheaper but carries quality and legal risks. MK-677 is dramatically more accessible.
In the US and most countries as of 2026, MK-677 is an unscheduled research chemical — no prescription is required. HGH is a Schedule III controlled substance in the US; a prescription is legally required to obtain it.
Neither is universally better — the right choice depends on your individual health profile, treatment goals, side effect tolerance, insurance coverage, and prescriber recommendation. Clinical trial data shows efficacy differences in specific populations, but personal response varies. Track your experience with either medication in Shotlee to generate objective comparison data with your healthcare provider.
Switching between these medications should be done under medical supervision. Your prescriber will consider factors including your current response, reason for switching, dose equivalence, and transition timing. Use Shotlee to document your outcomes on the current medication so you have a clear baseline for comparison after switching.
Track Mk 677 or Hgh in Shotlee
Free dose tracking, side effect logging, and outcome comparison for any medication protocol.